SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

2/9/22 9:19:56 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JAZZ alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 JAZZ PHARMACEUTICALS PLC COMMON STOCK Cusip #G50871105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G50871105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 208,936 Item 6: 0 Item 7: 1,702,656 Item 8: 0 Item 9: 1,702,656 Item 11: 2.764% Item 12: HC Cusip #G50871105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 1,702,656 Item 8: 0 Item 9: 1,702,656 Item 11: 2.764% Item 12: IN Item 1(a). Name of Issuer: JAZZ PHARMACEUTICALS PLC Item 1(b). Address of Issuer's Principal Executive Offices: 5TH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD DUBLIN, L2 4 IE Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: G50871105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 1,702,656 (b) Percent of Class: 2.764% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 208,936 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,702,656 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of JAZZ PHARMACEUTICALS PLC. No one other person's interest in the COMMON STOCK of JAZZ PHARMACEUTICALS PLC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of JAZZ PHARMACEUTICALS PLC at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $JAZZ alert in real time by email

Recent Analyst Ratings for

$JAZZ

Date	Price Target	Rating	Analyst
5/22/2026	$229.00	Mkt Perform	Bernstein
5/19/2026	$307.00	Neutral → Buy	UBS
4/10/2026	$227.00	Outperform	Raymond James
2/27/2026	$224.00	Overweight	Barclays
11/24/2025	$188.00	Buy → Neutral	UBS
7/15/2025	$152.00	Buy	Deutsche Bank
3/7/2025	$145.00 → $179.00	Neutral → Buy	UBS
2/26/2025		Overweight → Neutral	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

2/9/22 9:19:56 AM ET

$JAZZ

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JAZZ alert in real time by email

Recent Analyst Ratings for

$JAZZ

Date	Price Target	Rating	Analyst
5/22/2026	$229.00	Mkt Perform	Bernstein
5/19/2026	$307.00	Neutral → Buy	UBS
4/10/2026	$227.00	Outperform	Raymond James
2/27/2026	$224.00	Overweight	Barclays
11/24/2025	$188.00	Buy → Neutral	UBS
7/15/2025	$152.00	Buy	Deutsche Bank
3/7/2025	$145.00 → $179.00	Neutral → Buy	UBS
2/26/2025		Overweight → Neutral	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$JAZZ

SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$JAZZ

$JAZZ
Press Releases

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

$JAZZ
Analyst Ratings

Bernstein initiated coverage on Jazz Pharma with a new price target

Jazz Pharma upgraded by UBS with a new price target

Raymond James resumed coverage on Jazz Pharma with a new price target

$JAZZ
Insider Trading

Director Cozadd Bruce C sold $1,410,720 worth of Ordinary Shares (6,000 units at $235.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 372,682 units (SEC Form 4)

EVP & Chief Legal Officer Patil Neena M sold $282,468 worth of Ordinary Shares (1,192 units at $236.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 52,626 units (SEC Form 4)

EVP, Chief Commercial Officer Pearce Samantha exercised 6,907 units of Ordinary Shares at a strike of $109.45 and sold $1,625,977 worth of Ordinary Shares (6,907 units at $235.41) (SEC Form 4)

$JAZZ
Insider Purchases

Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

$JAZZ
SEC Filings

SEC Form 144 filed by Jazz Pharmaceuticals plc

SEC Form PRE 14A filed by Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc filed SEC Form 8-K: Leadership Update

$JAZZ
FDA approvals

August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

$JAZZ
Leadership Updates

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

$JAZZ
Financials

$JAZZ
Large Ownership Changes

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance